Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium - Comparison of clinico-pathological and survival outcomes

被引：0
|
作者：
Genova, L. [1 ]
Andreasi, V [1 ]
Partelli, S. [1 ]
Muffatti, F. [1 ]
Battistella, A. [1 ]
Crippa, S. [1 ]
Tamburrino, D. [1 ]
Pecorelli, N. [1 ]
Balzano, G. [1 ]
Falconi, M. [1 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Italy
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷
关键词：
peptide receptor radionuclide therapy; prrt; neoadjuvant; surgery; yttrium; lutetium;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H15
引用
收藏
页码：187 / 187
页数：1
相关论文
共 41 条
  • [31] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy Lu-177-DOTA-TATE (PRRT) Improves Progression Free Survival (PFS) in Patients with Advanced Neuroendocrine Tumours (NETs)
    McEwan, A. J. B.
    Wieler, M.
    Sawyer, M. B.
    Morrish, D. W.
    Schaitel, B. A.
    Schrader, L. D.
    Murray, D.
    Makis, W.
    McMullen, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S158 - S158
  • [32] Long-term side effects in patients with disseminated neuroendocrine tumors who underwent tandem peptide receptor radionuclide therapy (PRRT) with 90Y/177Lu-DOTATATE
    Kunikowska, J.
    Matyskiel, R.
    Pawlak, D.
    Krolicki, L.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [33] Repeated cycles of peptide receptor radionuclide therapy (PRRT) - Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET
    Pach, Dorota
    Sowa-Staszczak, Anna
    Kunikowska, Jolanta
    Krolicki, Leszek
    Trofimiuk, Malgorzata
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Glowa, Boguslaw
    Mikolajczak, Renata
    Pawlak, Dariusz
    Jabrocka-Hybel, Agata
    Hubalewska-Dydejczyk, Alicja B.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 (01) : 45 - 50
  • [34] Repeated cycles of peptide receptor radionuclide therapy (PRRT) - Side-effects and response to the radioisotope 90Y-DOTA-TATE or 90Y/177Lu DOTA-TATE therapy in patients with disseminated NET
    Sowa-Staszczak, Anna
    Kunikowska, Jolanta
    Krolicki, Leszek
    Mikolajczak, Renata
    Pawlak, Dariusz
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Trofimiuk, Malgorzata
    Pach, Dorota
    Hubalewska-Dydejczyk, Alicja
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [35] Peptide Receptor Radionuclide Therapy with 177Lutethium or 90Yttrium-DOTA-TATE or -TOC in Malignant Pheochromocytomas (PCCs) and Paragangliomas (PGLs): Results from a single institutional retrospective analysis
    Rubino, M.
    Di Stasio, G. D.
    Spada, F.
    Rocca, P. A.
    Laffi, A.
    Fazio, N.
    Bodei, L.
    Grana, C. M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 158 - 158
  • [36] Impact of two cycles of peptide receptor radionuclide therapy (PRRT) on renal function as determined by repeated Tc-99m DTPA/GFR measurements: comparison between Y-90 DOTA-TATE and Lu-177 DOTA-TATE
    Prasad, V.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S325 - S325
  • [37] Bone marrow dose results in peptide receptor radionuclide therapy (PRRT) with 90Y-DOTA-Tyr3-Octreotide, 111In-DTPA-Octreotide and 177Lu-DOTA-Octreotate:: Importance of dosimetry model.
    Konijnenberg, M
    Barone, R
    Walrand, S
    Jamar, F
    De Camps, J
    Pauwels, S
    Smith, C
    Kooij, P
    Kwekkeboom, DJ
    Valkema, R
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 90P - 90P
  • [38] Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy
    De Silva, Madhawa K.
    Chan, David L. H.
    Bernard, Elizabeth J.
    Conner, Alice J.
    Mascall, Sophie L.
    Bailey, Dale L.
    Roach, Paul J.
    Clarke, Stephen J.
    Diakos, Connie I.
    Pavlakis, Nick
    Schembri, Geoff
    PANCREAS, 2024, 53 (07) : e560 - e565
  • [39] Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTA0,Tyr3-octreotide (Y-Oc) and 111In-DTPA0-octreotide (In-Oc):: Comparison of tumor response and toxicity.
    Valkema, R
    Pauwels, S
    Kvols, L
    Bakker, WH
    Jamar, F
    Smith, C
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 34P - 34P
  • [40] Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18 F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak, Anna
    Kolodziej, Maciej
    Gut, Pawel
    Krolicki, Leszek
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    Ruchala, Marek
    Pawlak, Dariusz
    Kunikowska, Jolanta
    ENDOKRYNOLOGIA POLSKA, 2020, 71 (03) : 240 - 248
12345